

Giovanni Battista Gaeta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7934460/publications.pdf>

Version: 2024-02-01

38
papers

1,441
citations

566801

15
h-index

329751

37
g-index

38
all docs

38
docs citations

38
times ranked

1912
citing authors

#	ARTICLE	IF	CITATIONS
1	Combination of Tenofovir Disoproxil Fumarate and Peginterferon α -2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B. <i>Gastroenterology</i> , 2016, 150, 134-144.e10.	0.6	284
2	Chronic Hepatitis D: A Vanishing Disease? An Italian Multicenter Study. <i>Hepatology</i> , 2000, 32, 824-827.	3.6	228
3	Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. <i>Hepatology</i> , 2006, 44, 713-720.	3.6	222
4	Replicative and Transcriptional Activities of Hepatitis B Virus in Patients Coinfected with Hepatitis B and Hepatitis Delta Viruses. <i>Journal of Virology</i> , 2011, 85, 432-439.	1.5	88
5	Management of infections pre- and post-liver transplantation: Report of an AISF consensus conference. <i>Journal of Hepatology</i> , 2014, 60, 1075-1089.	1.8	77
6	Declining prevalence and increasing awareness of HCV infection in Italy: A population-based survey in five metropolitan areas. <i>European Journal of Internal Medicine</i> , 2018, 53, 79-84.	1.0	69
7	Fever of unknown origin (FUO): which are the factors influencing the final diagnosis? A 2005-2015 systematic review. <i>BMC Infectious Diseases</i> , 2019, 19, 653.	1.3	64
8	Hepatitis delta in Europe: Vanishing or refreshing?. <i>Hepatology</i> , 2007, 46, 1312-1313.	3.6	48
9	Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long-term tenofovir or entecavir. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1071-1076.	1.9	35
10	Hepatitis delta infection in Italian patients: towards the end of the story?. <i>Infection</i> , 2017, 45, 277-281.	2.3	34
11	Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?. <i>Journal of Hepatology</i> , 2018, 68, 597-600.	1.8	28
12	Characteristics of liver cirrhosis in Italy: Evidence for a decreasing role of HCV aetiology. <i>European Journal of Internal Medicine</i> , 2017, 38, 68-72.	1.0	23
13	Gender differences in chronic liver diseases in two cohorts of 2001 and 2014 in Italy. <i>Infection</i> , 2018, 46, 93-101.	2.3	22
14	Gender differences in chronic HBsAg carriers in Italy: Evidence for the independent role of male sex in severity of liver disease. <i>Journal of Medical Virology</i> , 2015, 87, 1899-1903.	2.5	19
15	The present profile of chronic hepatitis B virus infection highlights future challenges. <i>Digestive and Liver Disease</i> , 2019, 51, 438-442.	0.4	17
16	Italian consensus Guidelines for the management of hepatitis B virus infections in patients with rheumatoid arthritis. <i>Joint Bone Spine</i> , 2017, 84, 525-530.	0.8	15
17	Virological patterns of HCV patients with failure to interferon-free regimens. <i>Journal of Medical Virology</i> , 2018, 90, 942-950.	2.5	14
18	NS5A Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected Patients. <i>Cells</i> , 2019, 8, 666.	1.8	13

#	ARTICLE	IF	CITATIONS
19	Current and forthcoming perspectives in linkage to care of hepatitis C virus infection: Assessment of an Italian focus group. <i>Digestive and Liver Disease</i> , 2019, 51, 915-921.	0.4	13
20	ITPase Activity Modulates the Severity of Anaemia in HCV-Related Cirrhosis Treated with Ribavirin-Containing Interferon-Free Regimens. <i>Antiviral Therapy</i> , 2017, 22, 551-558.	0.6	12
21	Treatment of Acute Hepatitis C With Ledipasvir and Sofosbuvir in Patients With Hematological Malignancies Allows Early Re-start of Chemotherapy. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 977-978.	2.4	12
22	Treatment of chronic hepatitis due to hepatitis B and hepatitis delta virus coinfection. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 697-701.	1.1	11
23	An Increase in the Levels of Middle Surface Antigen Characterizes Patients Developing HBV-Driven Liver Cancer Despite Prolonged Virological Suppression. <i>Microorganisms</i> , 2021, 9, 752.	1.6	10
24	Italian consensus recommendations for the management of hepatitis C infection in patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2019, 29, 895-902.	0.9	9
25	Hepatitis delta coinfection in persons with HIV: misdiagnosis and disease burden in Italy. <i>Pathogens and Global Health</i> , 2023, 117, 181-189.	1.0	9
26	A randomized, controlled study of peginterferon lambda-1a/ribavirin±daclatasvir for hepatitis C virus genotype 2 or 3. <i>SpringerPlus</i> , 2016, 5, 1365.	1.2	8
27	Characteristics of patients with hepatitis C virus-related chronic liver diseases just before the era of oral direct-acting antiviral therapy in Italy. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 676-681.	0.8	8
28	Changing indications for liver transplant: slow decline of hepatitis viruses in Italy. <i>Infectious Diseases</i> , 2020, 52, 557-562.	1.4	8
29	Treatment of acute hepatitis C: recommendations from an expert panel of the Italian Society of Infectious and Tropical Diseases. <i>Infection</i> , 2018, 46, 183-188.	2.3	7
30	CD8 ⁺ T cells specific to apoptosis-associated epitopes are expanded in patients with chronic HBV infection and fibrosis. <i>Liver International</i> , 2021, 41, 470-481.	1.9	7
31	Optimizing patient referral and center capacity in the management of chronic hepatitis C: Lessons from the Italian experience. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2019, 43, 190-200.	0.7	6
32	Simeprevir and daclatasvir for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1b and advanced liver disease. <i>Liver International</i> , 2017, 37, 1304-1313.	1.9	5
33	Prophylaxis of Hepatitis B Virus (HBV) Re-Infection in Liver Transplantation: Is the Reappearance of Hepatitis B Surface Antigen (HBsAg) Significant?. <i>Annals of Transplantation</i> , 2020, 25, e920969.	0.5	5
34	Effectiveness and safety of simeprevir-based regimens for hepatitis C in Italy. <i>Medicine (United States)</i> , 2018, 97, e11307.	0.4	3
35	Prevalent use of combined prophylaxis of hepatitis B after liver transplantation in Italy: results of a national survey in a large cohort. <i>Minerva Gastroenterology</i> , 2017, 64, 1-9.	0.3	3
36	Management of hepatitis C positive patients undergoing active treatment for malignancies: A position paper from the Associazione Italiana di Oncologia Medica (AIOM) and the Società Italiana di Malattie Infettive e Tropicali (SIMIT). <i>Seminars in Oncology</i> , 2018, 45, 259-263.	0.8	2

#	ARTICLE	IF	CITATIONS
37	HBsAg seroconversion after pegylated interferon alfa 2a rescue in a lamivudine-resistant patient with HBeAg-negative chronic hepatitis B and favourable IL28-B genotype. <i>Infezioni in Medicina</i> , 2016, 24, 144-6.	0.7	2
38	Letter: clinical outcomes of patients with hepatitis D infection in the liver transplant setting—authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 484-484.	1.9	1